查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930164

全球猪疫苗市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量因素以及未来预测（2026-2034）

Porcine Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 请询问到货日

价格

猪隻疫苗市场成长因素

受猪病发病率上升、猪肉消费量增长以及畜牧卫生管理日益重视等因素的推动，全球猪隻疫苗市场持续稳步扩张。 根据2025年的报告，猪疫苗市场预计在2025年达到12.3亿美元，并在2026年成长至13亿美元。从长远来看，预计到2034年，该市场将达到23亿美元，这反映了疫苗接种在预防养猪业疾病爆发造成的经济损失方面发挥的重要作用。

疫苗是动物预防医学的基石，其设计目的是在不引起疾病的情况下，刺激身体对细菌、病毒和寄生虫等病原体产生免疫反应。在猪群中，疫苗接种在控制猪繁殖与呼吸综合症（PRRS）、猪瘟、猪流感和口蹄疫等高传染性疾病方面发挥着至关重要的作用。随着养殖集约化程度的提高和牲畜密度的增加，疾病传播的风险也在增加，因此疫苗接种计划对于维持猪群生产力和粮食安全至关重要。

市场概览及主要亮点

预计到2025年，北美将以17.74%的市场占有率引领猪疫苗市场，这得益于严格的动物健康法规、强大的食品安全标准以及预防性兽医保健的广泛应用。该地区持续开展针对高影响猪病的研究项目和疫苗开发计划，进一步巩固了其领先地位。美国在其中扮演着至关重要的角色，因为猪繁殖与呼吸综合症（PRRS）造成了巨大的经济负担，仅此一项每年就造成约5.6亿美元的损失。

亚太地区是成长最快的区域市场，这主要得益于高猪肉产量、不断提高的生物安全意识以及政府主导的疫苗接种计划的增加。中国和日本等国家正在强调群体免疫的重要性，以保护其庞大的猪肉供应链。 由于猪流感的高发生率（估计有 56.6% 的猪群受到影响）以及该地区对先进基因型特异性疫苗的强有力的监管支持，欧洲占了相当大的市场占有率。

市场动态

市场驱动因素

猪群疾病发生率的上升和全球猪肉消费量的成长是市场成长的关键驱动因素。全球生产数据显示，到 2023 年，猪肉产量将达到约 1.2467 亿吨，凸显了健康牲畜满足蛋白质需求的重要性。人们对人畜共通传染病传播的认识不断提高，进一步促使畜牧生产者投资于常规疫苗接种，以保护动物和人类的健康。

市场限制因子

发展中地区疫苗接种率有限，继续限制市场成长。兽医基础设施不足、意识薄弱和资金限制等因素阻碍了疫苗的普及。 研究表明，发展中国家约 50.0% 的可预防牲畜死亡与传染病有关，凸显了疫苗接种覆盖率的差距。

市场机会

政府支持的疫苗接种计划提供了巨大的成长机会。政府致力于预防经典猪瘟和猪繁殖与呼吸综合症 (PRRS) 的各项措施正在扩大疫苗的供应。针对数十万头猪的大规模疫苗接种活动正在增强新兴市场对猪隻疫苗的需求。

市场挑战

PRRS 和猪流感等病原体的快速基因突变会造成疫苗不相容的风险，降低疫苗效力，并需要频繁地重新配製疫苗。 此外，复杂的监管架构和冗长的审批流程会延缓产品上市，为生产商带来挑战。

市场趋势

猪免疫技术的进步，特别是基因型特异性疫苗的研发，是该产业的主要趋势。这些疫苗利用基因组数据更精准地针对流行病原体株，增强免疫反应并控制疾病。生物技术和疫苗配方方面的创新正在改善猪群健康，并减少与呼吸道疾病相关的经济损失。

市场区隔分析

依产品分类

灭活疫苗因其卓越的安全性和抑制病毒爆发的有效性而占市场主导地位。减毒活疫苗也占了相当大的占有率，这得益于其诱导长期免疫的能力。 重组疫苗因其靶向免疫反应和成本效益高的生产方式而备受关注。

依给药途径

由于其快速活化免疫反应和高效性，肠外给药途径占市场主导地位。口服疫苗因其给药方便且易于规模化，预计将增长更快，尤其是在大规模疫苗接种计划中。

依分销管道

兽医院凭藉其先进的诊断和治疗能力，占最大的市场占有率。动物诊所和研究机构透过常规疫苗接种服务和持续的疫苗研发，稳步贡献市场占有率。

"全球猪疫苗市场（2025）" 报告对2025年、2026年和2034年的市场规模和价值进行了全面分析，涵盖产品细分、给药途径、分销渠道、区域表现、竞争格局、主要行业趋势以及新冠疫情的影响。 本报告重点关注疾病流行情况、疫苗接种指南以及塑造猪免疫未来发展的创新趋势。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家和地区猪病概览（2025 年）
  • 主要国家及地区监理现况（2025 年）
  • 猪病疫苗接种概览
  • 主要公司新产品发布
  • 主要产业趋势：併购、业务合作等
  • 影响COVID-19 对全球猪隻疫苗市场的影响

第五章 全球猪隻疫苗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依产品分类
    • 灭活​​疫苗
    • 减毒活疫苗
    • 重组疫苗
    • 其他
  • 市场分析、洞察与预测：依给药途径
    • 口服
    • 注射
  • 市场分析、洞察与预测：依销售管道
    • 兽医院
    • 兽医诊所
    • 药局
    • 其他
  • 市场分析、洞察与预测：依地区
    • 北美美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美猪疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲猪疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚半岛
    • 其他欧洲国家

第八章 亚太猪疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲猪疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲猪疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会（GCC）国家
    • 南亚非洲
    • 中东和非洲其他地区

第11章 竞争分析

  • 世界市场占有率分析(2025年)
  • 企业简介
    • Elanco
    • HIPRA
    • Boehringer Ingelheim International GmbH
    • Virbac
    • Merck &Co., Inc.
    • Zoetis Services LLC
    • Ceva
    • NEOGEN CORPORATION
    • Hester Biosciences Limited
Product Code: FBI112834

Growth Factors of porcine vaccines Market

The global porcine vaccines market is witnessing steady expansion, driven by the increasing prevalence of swine diseases, rising pork consumption, and the growing emphasis on livestock health management. According to the 2025 report year, the porcine vaccines market was valued at USD 1.23 billion in 2025 and is projected to grow to USD 1.30 billion in 2026. Over the long-term forecast horizon, the market is expected to reach USD 2.30 billion by 2034, reflecting the essential role of vaccination in preventing economic losses associated with disease outbreaks in pig farming.

Vaccines are a cornerstone of preventive veterinary healthcare, designed to stimulate immune responses against pathogens such as bacteria, viruses, and parasites without causing disease. In pig populations, vaccination plays a critical role in controlling highly contagious conditions such as Porcine Reproductive and Respiratory Syndrome (PRRS), classical swine fever, swine influenza, and foot-and-mouth disease. Increasing farm intensification and dense animal populations have heightened disease transmission risks, making vaccination programs indispensable for maintaining herd productivity and food security.

Market Overview and Key Highlights

In 2025, North America dominated the porcine vaccines market with a 17.74% market share, supported by strict animal health regulations, strong food safety standards, and widespread adoption of preventive veterinary care. The region's leadership is reinforced by continuous research initiatives and vaccine development programs targeting high-impact swine diseases. The U.S. plays a pivotal role due to the high economic burden of PRRS, which alone costs the industry approximately USD 560.0 million annually.

Asia Pacific represents the fastest-growing regional market, fueled by high pork production volumes, rising awareness of biosecurity, and increasing government-led vaccination initiatives. Countries such as China and Japan are emphasizing herd immunity to protect large-scale pork supply chains. Europe holds a significant share due to the high prevalence of swine influenza, affecting an estimated 56.6% of herds, and the region's strong regulatory support for advanced genotype-specific vaccines.

Market Dynamics

Market Drivers

The rising prevalence of swine diseases and increasing global pork consumption are key drivers of market growth. According to global production data, pig meat output reached approximately 124.67 million tons in 2023, underscoring the need for healthy livestock to meet protein demand. Awareness of zoonotic disease transmission has further encouraged farmers to invest in routine vaccination to safeguard animal and human health.

Market Restraints

Limited adoption of immunization in developing regions continues to restrain market growth. Factors such as inadequate veterinary infrastructure, low awareness, and financial constraints hinder vaccine penetration. Studies indicate that nearly 50.0% of preventable livestock deaths in developing countries are linked to infectious diseases, highlighting gaps in vaccination coverage.

Market Opportunities

Government-supported vaccination programs offer significant growth opportunities. Public initiatives focusing on classical swine fever and PRRS prevention are expanding vaccine accessibility. Large-scale immunization campaigns targeting hundreds of thousands of pigs are strengthening demand for porcine vaccines across emerging markets.

Market Challenges

Rapid genetic mutations in pathogens such as PRRS virus and swine influenza create vaccine mismatch risks, reducing efficacy and requiring frequent reformulation. Additionally, complex regulatory frameworks and lengthy approval processes can delay product launches, posing challenges for manufacturers.

Market Trends

Technological advancements in porcine immunization, particularly the development of genotype-specific vaccines, represent a major industry trend. These vaccines leverage genomic data to target prevalent pathogen strains more precisely, improving immune response and disease control. Innovations in biotechnology and vaccine formulation are enhancing herd health outcomes and reducing economic losses linked to respiratory disease complexes.

Segmentation Analysis

By Product

The inactivated vaccines segment held a dominant share due to its strong safety profile and effectiveness in controlling viral outbreaks. Live attenuated vaccines also accounted for a substantial share, supported by their ability to induce long-lasting immunity. Recombinant vaccines are gaining traction due to targeted immune responses and cost-efficient production.

By Route of Administration

The parenteral route leads the market, driven by rapid immune activation and high efficacy. Oral vaccines are expected to grow faster, particularly for mass vaccination programs, due to ease of administration and scalability.

By Distribution Channel

Veterinary hospitals account for the largest share, supported by advanced diagnostic and treatment capabilities. Veterinary clinics and research institutes contribute steadily through routine immunization services and ongoing vaccine development.

Competitive Landscape

The porcine vaccines market is moderately consolidated, with key players including Zoetis Services LLC, Merck & Co., Inc., Elanco, Virbac, and Ceva. These companies focus on expanding product portfolios, strategic acquisitions, and geographic expansion to strengthen market presence.

Report Coverage

The 2025 porcine vaccines market report provides a comprehensive analysis of market size and value for 2025, 2026, and 2034, covering product segmentation, routes of administration, distribution channels, regional performance, competitive landscape, key industry developments, and the impact of COVID-19. The report emphasizes disease prevalence, vaccination guidelines, and innovation trends shaping the future of porcine immunization.

Conclusion

The global porcine vaccines market is expected to maintain steady and sustainable growth throughout the forecast period, supported by the rising prevalence of swine diseases, increasing pork consumption, and growing awareness of preventive animal healthcare. With the market valued at USD 1.23 billion in 2025, projected to reach USD 1.30 billion in 2026, and further expanding to USD 2.30 billion by 2034, the outlook highlights the critical role of vaccination in protecting herd health and minimizing economic losses in pig farming. North America's leadership, holding 17.74% market share in 2025, reflects the impact of stringent animal health regulations and advanced veterinary infrastructure, while Asia Pacific's rapid growth underscores expanding vaccination initiatives and high pork production volumes. Despite challenges such as limited immunization adoption in developing regions, pathogen mutation, and regulatory complexity, continuous technological advancements, genotype-specific vaccines, and strong government-backed vaccination programs are strengthening market fundamentals. Overall, the porcine vaccines market is well-positioned for long-term expansion, driven by innovation, disease prevention priorities, and the global demand for safe and sustainable animal protein.

Segmentation By Product

  • Inactivated
  • Live Attenuated
  • Recombinant
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Veterinary Hospitals
  • Veterinary Clinics
  • Pharmacies & Drug Stores
  • Others

By Region

  • North America (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • U.S.
    • Canada
  • Europe (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of Porcine Diseases by Key Countries, By Key Countries/ Region, 2025
  • 4.2. Regulatory Scenario by Key Countries/ Region, 2025
  • 4.3. Overview of Vaccination for Porcine Diseases
  • 4.4. New Product Launches, By Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.6. Impact of COVID-19 on the Global Porcine Vaccines Market

5. Global Porcine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Inactivated
    • 5.1.2. Live Attenuated
    • 5.1.3. Recombinant
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Veterinary Hospitals
    • 5.3.2. Veterinary Clinics
    • 5.3.3. Pharmacies & Drug Stores
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Porcine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Inactivated
    • 6.1.2. Live Attenuated
    • 6.1.3. Recombinant
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Veterinary Hospitals
    • 6.3.2. Veterinary Clinics
    • 6.3.3. Pharmacies & Drug Stores
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Porcine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Inactivated
    • 7.1.2. Live Attenuated
    • 7.1.3. Recombinant
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Veterinary Hospitals
    • 7.3.2. Veterinary Clinics
    • 7.3.3. Pharmacies & Drug Stores
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. Germany
    • 7.4.2. U.K.
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Porcine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Inactivated
    • 8.1.2. Live Attenuated
    • 8.1.3. Recombinant
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Veterinary Hospitals
    • 8.3.2. Veterinary Clinics
    • 8.3.3. Pharmacies & Drug Stores
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Porcine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Inactivated
    • 9.1.2. Live Attenuated
    • 9.1.3. Recombinant
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Veterinary Hospitals
    • 9.3.2. Veterinary Clinics
    • 9.3.3. Pharmacies & Drug Stores
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Porcine Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Inactivated
    • 10.1.2. Live Attenuated
    • 10.1.3. Recombinant
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Veterinary Hospitals
    • 10.3.2. Veterinary Clinics
    • 10.3.3. Pharmacies & Drug Stores
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Elanco
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. HIPRA
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Boehringer Ingelheim International GmbH
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Virbac
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Merck & Co., Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Zoetis Services LLC
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Ceva
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. NEOGEN CORPORATION
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Hester Biosciences Limited
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 2: Global Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Porcine Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 6: North America Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 7: North America Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Porcine Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 10: Europe Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 11: Europe Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Porcine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 14: Asia Pacific Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 15: Asia Pacific Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Porcine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 18: Latin America Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Latin America Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Porcine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Porcine Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 22: Middle East & Africa Porcine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 23: Middle East & Africa Porcine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Porcine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Porcine Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Porcine Vaccines Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Porcine Vaccines Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Porcine Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Porcine Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Porcine Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 7: North America Porcine Vaccines Market Value Share (%), by Product, 2025
  • Figure 8: North America Porcine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 9: North America Porcine Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 10: North America Porcine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Porcine Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Porcine Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Porcine Vaccines Market Value Share (%), By Country, 2025
  • Figure 14: Europe Porcine Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 15: Europe Porcine Vaccines Market Value Share (%), by Product, 2025
  • Figure 16: Europe Porcine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 17: Europe Porcine Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 18: Europe Porcine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Porcine Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Porcine Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Porcine Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Porcine Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 23: Asia Pacific Porcine Vaccines Market Value Share (%), by Product, 2025
  • Figure 24: Asia Pacific Porcine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 25: Asia Pacific Porcine Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 26: Asia Pacific Porcine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Porcine Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Porcine Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Porcine Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Porcine Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 31: Latin America Porcine Vaccines Market Value Share (%), by Product, 2025
  • Figure 32: Latin America Porcine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 33: Latin America Porcine Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 34: Latin America Porcine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Porcine Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Porcine Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Porcine Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Porcine Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 39: Middle East & Africa Porcine Vaccines Market Value Share (%), by Product, 2025
  • Figure 40: Middle East & Africa Porcine Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 41: Middle East & Africa Porcine Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 42: Middle East & Africa Porcine Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Porcine Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Porcine Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Porcine Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Porcine Vaccines Market Share (%), By Company, 2025